3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
9
Carcinoma, Transitional Cell
4
Neoplasms
3
Neoplasm Metastasis
3
Breast Neoplasms
3
Ureteral Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Renal Insufficiency
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Kidney Neoplasms
1
Interventions
Gemcitabine
7
Cisplatin
5
pembrolizumab
4
enfortumab vedotin
4
Mitomycin
4
Trastuzumab
3
Pemetrexed
3
Carboplatin
3
dodecyl maltoside
2
atezolizumab
2
Sunitinib
2
vinflunine
1
valrubicin
1
tucatinib
1
palbociclib
1
niraparib
1
motexafin gadolinium
1
cabozantinib
1
avelumab
1
apatorsen
1
Water
1
VMBP protocol
1
Standard of Care
1
Radiation Dose Hypofractionation
1
Nivolumab
1
Neoadjuvant Therapy
1
Immunoglobulins, Intravenous
1
Gels
1
GSK-3326595
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urologic Neoplasms
×
vinflunine
×
Clear all
NCT01599013
2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2
Completed
69 enrolled